Reporting

To support monitoring and evaluation of OPIP, participating sites must provide standardised information on tirzepatide (Mounjaro®) prescribing, patient access and delivery through their approved innovative care models. This will enable NHS England to assess programme rollout and compare the effectiveness, accessibility and scalability of the approaches being tested. The reporting schedule is set out below:

Each participating OPIP site has provided NHS England with details of two nominated reporters. These reporters will have access to the Data Collections Framework to submit aggregated data for their site on tirzepatide (Mounjaro®) prescribing, patient access and delivery through the approved OPIP model. Access details for the reporting framework have been shared with the nominated reporters through the relevant ICB.

If you believe you should be a nominated reporter with access to the platform, please contact your ICB.

To support evaluation of OPIP, NHS England requires participating ICBs to submit quarterly data on tirzepatide (Mounjaro®) prescribing, patient access and delivery through each approved innovative care model. Consistent reporting will enable NHS England to monitor programme rollout, compare approaches across sites and assess their effectiveness, accessibility and scalability. The findings will inform future programme development, commissioning and funding decisions.

The quarterly reports include the following indicators:

1. Number of patients assessed for eligibility for tirzepatide (Mounjaro®) through the Obesity Pathway Innovation Programme
2. Number of patients prescribed tirzepatide (Mounjaro®) through the Obesity Pathway Innovation Programme
3. Number of patients referred to the national wraparound care service through the Obesity Pathway Innovation Programme
4. Number of patients referred to locally commissioned wraparound care through the Obesity Pathway Innovation Programme
5. Number of eligible patients who declined tirzepatide (Mounjaro®) through the Obesity Pathway Innovation Programme
6. Number of patients who stopped tirzepatide (Mounjaro®) after starting treatment through the Obesity Pathway Innovation Programme

The reporting framework requests above information broken down by:

1. Ethnic background (Asian, Black, Mixed, Other, White, unknown)
2. Quintiles of Deprivation NHSE DCF template uses Quintiles of Deprivation (IMD 1 to IMD 5, where IMD 1 is the most deprived and IMD 5 is the least deprived). IMD 1 to IMD 10 are Deciles are deprivation. For more information – (1) Public Health Technical Guidance – Using the English indices of deprivation  (2) English indices of deprivation 2019 - GOV.UK
3. Sex: The sex the patient is registered as with their general practice
4. Severe Mental Illness (SMI): A diagnosis of schizophrenia, bipolar affective disorder or who have experienced an episode of non-organic psychosis 
5. Learning Disability (LD): A formally recorded diagnosis of a learning disability. This is different to a learning difficulty, which is a type of special educational need, such as dyslexia, or other condition which affects only one area of learning (such as reading, writing, spelling or maths) 
6. Delivery Models: Each OPIP site may adopt the delivery approach set out in its approved proposal, based on local population needs, service arrangements and the innovative model being tested. “Custom Model” should be used only where the approved approach does not align with any of the standard reporting categories.

Through systematic reporting on these indicators NHS England aims to monitor the prescribing of tirzepatide (Mounjaro®) for the management of obesity and understand:

1. Patient sccess: The number of patients who have been prescribed tirzepatide (Mounjaro®) for the management of obesity, including demographic details and eligibility criteria.
2. Prescribing practices: Patterns and trends in prescribing tirzepatide (Mounjaro®) for the management of obesity, including adherence to clinical guidelines and any variations observed.
3. Resource utilisation: Analysis of the resources used in the implementation of tirzepatide (Mounjaro®) for the management of obesity, including financial costs and healthcare provider time.
4. Equity of access: Assessment of whether all eligible patients have equitable access to tirzepatide (Mounjaro®) for the management of obesity, considering factors such as geographic location and socioeconomic status.